SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ:ILMN) today announced that it is making available three new product solutions for cancer research, which include expansion of Illumina’s proprietary DASL® Assay to whole-genome profiling, and the launch of DASL focused expression and methylation profiling on Illumina’s VeraCode® technology. These new solutions allow researchers to leverage synergies across Illumina technology platforms to better understand the complex molecular mechanisms that give rise to cancer.
